Lucid Diagnostics Inc. Common Stock
LUCDLucid Diagnostics Inc. is a healthcare company focused on early detection and diagnosis of gastrointestinal cancers. Through its proprietary technology and testing methods, it aims to improve patient outcomes by providing non-invasive, accurate diagnostic solutions for conditions such as esophageal and other gastrointestinal cancers.
Company News
Lucid Diagnostics will host a business update conference call on November 12, 2025, at 8:30 AM ET, where CEO Lishan Aklog will discuss company operations and growth strategy, and CFO Dennis McGrath will review Q3 2025 financial results.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the closing on October 18, 2021 of its initial public offering (the “Offering”) of 5,000,000 sh...
